| 5.05 0.59 (13.23%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.1 | 1-year : | 7.13 |
| Resists | First : | 5.23 | Second : | 6.1 |
| Pivot price | 4.39  |
|||
| Supports | First : | 4.22 | Second : | 3.6 |
| MAs | MA(5) : | 4.35 |
MA(20) : | 4.41 |
| MA(100) : | 4.75 |
MA(250) : | 5.28 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 58.6 |
D(3) : | 41.6 |
| RSI | RSI(14): 61.1 |
|||
| 52-week | High : | 7.13 | Low : | 3.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CSBR ] has closed Bollinger Bands are 121.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.12 - 5.14 | 5.14 - 5.16 |
| Low: | 4.36 - 4.37 | 4.37 - 4.39 |
| Close: | 5.02 - 5.05 | 5.05 - 5.09 |
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Fri, 13 Sep 2024
Champions Oncology First Quarter 2025 Earnings: EPS: US$0.097 (vs US$0.19 loss in 1Q 2024) - Simply Wall St
Thu, 12 Sep 2024
Earnings call: Champions Oncology reports positive momentum in Q1 FY2025 By Investing.com - Investing.com Australia
Thu, 12 Sep 2024
Champions Oncology, Inc. (NASDAQ:CSBR) Q1 2025 Earnings Call Transcript - Insider Monkey
Thu, 12 Sep 2024
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Wed, 11 Sep 2024
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million - StockTitan
Wed, 11 Sep 2024
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 25.5 (%) |
| Held by Institutions | 50.9 (%) |
| Shares Short | 48 (K) |
| Shares Short P.Month | 49 (K) |
| EPS | -0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.15 |
| Profit Margin | -14.6 % |
| Operating Margin | 1.1 % |
| Return on Assets (ttm) | -14.4 % |
| Return on Equity (ttm) | -532.5 % |
| Qtrly Rev. Growth | 7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.69 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -9.36 |
| PEG Ratio | -2.4 |
| Price to Book value | -36.08 |
| Price to Sales | 1.36 |
| Price to Cash Flow | -11.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|